Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06698198 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years)
A Phase 1 study of Pneumococcal Immunization, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 175
- Enrollment target
- 2
- Study locations
NCT06698198 is a Phase 1 study of Pneumococcal Immunization that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 175 participants, below the 1,538-participant average among 3 other Pneumococcal Immunization trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06698198, a Phase 1 study of Pneumococcal Immunization, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 175 participants
- Enrollment target
- 2
- Study locations
Study Summary
This was a Phase I, randomized, active-controlled, observer-blinded, multi-center study to assess the safety and the immunogenicity of 4 Pneumococcal Conjugate Vaccines (PCV) candidates in parallel with Prevnar 13, in Healthy Adults (19-49 years) in the United States.
Conditions Studied
Interventions
- BIOLOGICAL Prevnar 13®
- BIOLOGICAL Pneumococcal Conjugate Vaccine
Study Locations (2)
Louisiana
- Investigational Site Number: 0002 - Metairie
New Jersey
- Investigational Site Number: 0001 - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2018-12-03 |
| Est. Completion | 2019-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06698198
The ClinicalTrials.gov registry entry for NCT06698198 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,538-participant average among 3 other Pneumococcal Immunization trials with a reported enrollment target (89% lower). The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pneumococcal Immunization appearing as the primary indexed condition, and to 2 interventions - of which Prevnar 13® is the first listed.
NCT06698198 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Louisiana, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06698198 about?
NCT06698198 is a clinical study titled "Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years)". This was a Phase I, randomized, active-controlled, observer-blinded, multi-center study to assess the safety and the immunogenicity of 4 Pneumococcal Conjugate Vaccines (PCV) candidates in parallel with Prevnar 13, in Healthy Adults (19-49 years) in the United States.
What is the current status of trial NCT06698198?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 175 participants. The study started on 2018-12-03. Estimated completion is 2019-09-30.
What conditions does trial NCT06698198 study?
This clinical trial studies the following conditions: Pneumococcal Immunization.
What interventions are being tested in trial NCT06698198?
The interventions under investigation include: Prevnar 13® (BIOLOGICAL), Pneumococcal Conjugate Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT06698198?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06698198 being conducted?
This trial has 2 study locations across Louisiana, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pneumococcal Immunization
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
RECRUITING · Phase 3
-
Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
ACTIVE NOT RECRUITING · Phase 3
-
Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.